Pitt Street Research sees strong upside in Prescient Therapeutics as one of the most advanced oncology companies on the ASX .

This study provides valuable findings regarding potential correlates of protection against the African swine fever virus. The evidence supporting the claims is solid, although analysis using a higher ...

Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a trial of PTX-100 for patients ...

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

Nasus Pharma has filed to raise $11M in an IPO of its ordinary shares, according to SEC F-1 registration. Read why my outlook ...

The rapid lateral flow assay from Lumos Diagnostics distinguishes bacterial and nonbacterial respiratory infections using a drop of blood.

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

The benchmarking report used a rigorous methodology to ensure results reflected ICON’s true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Joint Press release from Bambino Gesù Children’s Hospital, Rome; Department of Biochemistry and Gurdon Institute, University ...